Clinical Trials on Adult Acute Myelomonocytic Leukemia

Total 4857 results

Tel-Aviv Sourasky Medical Center

Unknown

Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT)

Juvenile Myelomonocytic Leukemia | Myelodysplastic Syndrome | Acute Leukemias | Chronic Leukemias
H. Lee Moffitt Cancer Center and Research Institute
Incyte Corporation

Completed

A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib

Myelomonocytic Leukemia

United States
Groupe Francophone des Myelodysplasies
Janssen-Cilag Ltd.

Completed

Decitabine in Patients With Chronic Myelomonocytic Leukemia (CMML)

Chronic Myelomonocytic Leukemia

France
Case Comprehensive Cancer Center

Active, not recruiting

CPX-351 as a Novel Approach for the Treatment of Older Patients With AML and MDS

Myelodysplastic Syndromes | Refractory Acute Myeloid Leukemia | Relapsed Acute Myelomonocytic Leukemia

United States
Celgene

Completed

Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia

Myelodysplastic Syndromes (MDS) | Chronic Myelomonocytic Leukemia (CMML) | Acute Myelogenous Leukemia (AML)

United States
Foghorn Therapeutics Inc.

Recruiting

FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies

Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Relapsed Acute Myeloid Leukemia | Relapsed Myelodysplastic Syndromes | Refractory Myelodysplastic Syndromes | Advanced Hematologic Malignancy | Relapsed Chronic Myelomonocytic Leukemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

FLT3 Gene Mutation Negative | FLT3 Internal Tandem Duplication Positive | Recurrent Acute Myeloid Leukemia | Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic...

United States
National Cancer Institute (NCI)

Not yet recruiting

TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Refractory Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory High Risk Myelodysplastic Syndrome
Fondazione Italiana Sindromi Mielodisplastiche-ETS
Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte

Completed

Multicenter Study to Assess the Efficacy of Decitabine in the Treatment of Chronic Myelomonocytic Leukemia (DECI2009)

Chronic Myelomonocytic Leukemia

Italy
National Cancer Institute (NCI)

Completed

Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer

Thrombocytopenia | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13... and other conditions

United States
Novartis Pharmaceuticals

Completed

A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia

Belgium, Hungary, Spain, Germany, Canada, Switzerland, Thailand, Korea, Republic of, United Kingdom, Italy, Austria, Sweden, France, United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS

Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Adult Acute Lymphoblastic Leukemia | Refractory Anemia With Excess Blasts

United States
Institute of Hematology & Blood Diseases Hospital

Not yet recruiting

LILRB4 STAR-T Cell Therapy for Monocytic Leukemia

Chronic Myelomonocytic Leukemia | Acute Myelogenous Leukemia

China
Kura Oncology, Inc.

Completed

Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid Leukemia (CMML/AML)

Leukemia, Myelomonocytic, Chronic

United States
Humanigen, Inc.

Completed

Study of Lenzilumab in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML)

Chronic Myelomonocytic Leukemia (CMML)

United States
National Cancer Institute (NCI)

Completed

CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase

Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) and other conditions

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation

Polycythemia Vera | Essential Thrombocythemia | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult... and other conditions

United States
Indiana University

Withdrawn

High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia, Adult | Bone Marrow Transplant Complications

United States
University of Arkansas

Terminated

The Expression of PTEN Protein and mRNA in Malignant Cells of Chronic Myelomonocytic Leukemia

Chronic Myelomonocytic Leukemia

United States
Centre Hospitalier Universitaire de Nice

Unknown

Relevance of Peripheral Cells in the Pathophysiology of Chronic Myelomonocytic Leukemia (CMML)

Chronic Myelomonocytic Leukemia

France
National Cancer Institute (NCI)

Completed

Combination Chemotherapy Followed By Donor Bone Marrow or Umbilical Cord Blood Transplant in Treating Children With Newly Diagnosed Juvenile Myelomonocytic Leukemia

Juvenile Myelomonocytic Leukemia

United States
University of Southern California
National Cancer Institute (NCI); Van Andel Research Institute

Active, not recruiting

Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed

Chronic Myelomonocytic Leukemia | Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes | Myelodysplastic Syndrome

United States
Astex Pharmaceuticals, Inc.

Completed

Study of ASTX727 vs IV Decitabine in MDS, CMML, and AML

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia

United States, Canada, Spain, Hungary, Austria, Czechia, France, Germany, Italy, United Kingdom
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and sAML

Myelodysplastic Syndromes | Secondary Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia-2

China
National Cancer Institute (NCI)

Terminated

Cilengitide in Treating Patients With Acute Myeloid Leukemia

Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia Without Maturation (M1) | Adult Acute Myeloid Leukemia With 11q23 (MLL)... and other conditions

United States
National Cancer Institute (NCI)

Completed

Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia

Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Chronic Myelomonocytic Leukemia | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic... and other conditions

United States
Douglas Tremblay
Sobi, Inc.

Not yet recruiting

Pacritinib in CMML

Chronic Myelomonocytic Leukemia

United States
Huda Salman
The Leukemia and Lymphoma Society; iCell Gene Therapeutics

Recruiting

Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML.

Chronic Myelomonocytic Leukemia

United States
M.D. Anderson Cancer Center
Syros Pharmaceuticals Inc.

Withdrawn

Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic Leukemia

Chronic Myelomonocytic Leukemia

United States
Case Comprehensive Cancer Center

Completed

High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma

Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent... and other conditions

United States
Fred Hutchinson Cancer Center
HighPass Bio, Inc.

Suspended

HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Acute Myeloid Leukemia | Leukemia | Chronic Myelomonocytic Leukemia | Juvenile Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | Chronic Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Refractory... and other conditions

United States
M.D. Anderson Cancer Center

Recruiting

Tagraxofusp and Decitabine for the Treatment of Chronic Myelomonocytic Leukemia

Chronic Myelomonocytic Leukemia | Myelodysplastic/Myeloproliferative Neoplasm | Chronic Myelomonocytic Leukemia-1 | Chronic Myelomonocytic Leukemia-2

United States
National Cancer Institute (NCI)

Terminated

17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer

Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Myelodysplastic Syndrome With Excess Blasts | Chronic Myelomonocytic Leukemia-1 | Chronic Myelomonocytic Leukemia-2 | Myelodysplastic Syndrome With Excess Blasts-1 | Myelodysplastic Syndrome/Acute Myeloid Leukemia

Canada, United States
H. Lee Moffitt Cancer Center and Research Institute
Incyte Corporation

Active, not recruiting

Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion

Leukemia | Chronic Myelomonocytic Leukemia

United States
National Cancer Institute (NCI)

Completed

Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases

Primary Myelofibrosis | Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Disease | Recurrent Adult Acute Lymphoblastic Leukemia | Secondary Myelodysplastic Syndrome | de Novo Myelodysplastic... and other conditions

United States, Canada, New Zealand
M.D. Anderson Cancer Center

Recruiting

Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Myelodysplastic Syndrome | Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia-1 | Chronic Myelomonocytic Leukemia-2 | Chronic Myelomonocytic Leukemia-0

United States
Imperial College London

Not yet recruiting

Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial (MAST)

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Chronic Myeloid Leukemia | Myelodysplastic Syndrome | Acute Leukemia of Ambiguous Lineage | Acute Lymphoblastic Leukaemia

United Kingdom
First Affiliated Hospital Xi'an Jiaotong University

Recruiting

Umbilical Cord Blood Transfusion in Consolidation Therapy of Elderly Patients With Acute Myeloid Leukemia

Leukemia, Myelomonocytic, Acute

China
Indiana University
OSI Pharmaceuticals

Completed

Pilot Study of Erlotinib for the Treatment of Patients With de Novo Acute Myeloid Leukemia

Leukemia, Myelomonocytic, Acute

United States
Mayo Clinic

Recruiting

Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia

Recurrent Chronic Myelomonocytic Leukemia | Refractory Chronic Myelomonocytic Leukemia

United States
University of Washington
National Cancer Institute (NCI)

Completed

Clofarabine, Cytarabine, and G-CSF in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) | Adult... and other conditions

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Symptom-Adapted Physical Activity Intervention in Minimizing Physical Function Decline in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8... and other conditions

United States
Nerviano Medical Sciences

Recruiting

Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML

Acute Myeloid Leukemia (AML) | Chronic Myelomonocytic Leukemia (CMML)

Italy, Spain, France
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous Leukemia

Chronic Myelomonocytic Leukemia | Chronic Myelogenous Leukemia

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Withdrawn

Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8... and other conditions
University of Utah
Genzyme, a Sanofi Company

Terminated

Low-dose Oral Clofarabine for the Treatment of IPSS INT-1, INT-2 or HIGH Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

Cancer | Chronic Myelomonocytic Leukemia

United States
National Cancer Institute (NCI)

Completed

PXD101 in Treating Patients With Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8... and other conditions

United States
Massachusetts General Hospital
Celgene

Completed

IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia

United States

Clinical Trials on Adult Acute Myelomonocytic Leukemia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lebanon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations